On April 10, 2017, AusCann Group Holdings Ltd (ASX:AC8) announced that it had started harvesting its first medical cannabis crop in Chile through DayaCann, a joint venture between AusCann and the Daya Foundation, a non-profit based in Chile that advocates for alternative therapies.
“We are very excited about our partnership with AusCann and this initial successful crop harvest and look forward to delivering the resulting medicines to our patients,” said Nicolás Dormal, founder of the Daya Foundation.
According to AusCann, nearly 700 pounds of dried cannabis sourced from the harvest will be delivered to a GMP-certified manufacturing facility where it will be processed into medicinal formulations. If the formulations make it through clinical trials successfully, they will be registered with the Chilean National Institute of Public Health and then made available to patients.
“We’re delighted with the harvest of our first crop with our partner Fundacion Daya and we’re confident we have selected the strongest and most appropriate strains for effective medicine formulations and further cultivation in the next harvest,” said Elaine Darby, AusCann’s Managing Director. “AusCann is also looking at leveraging this knowledge gained from Chile into the Australian market,” Darby added.